- Home
- ALRN vs BEAT Comparison
ALRN vs BEAT Comparison
Compare ALRN & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALRN
- BEAT
- Stock Information
- Founded
- ALRN 2001
- BEAT 2015
- Country
- ALRN United States
- BEAT United States
- Employees
- ALRN N/A
- BEAT N/A
- Industry
- ALRN Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- ALRN Health Care
- BEAT Technology
- Exchange
- ALRN Nasdaq
- BEAT Nasdaq
- Market Cap
- ALRN 76.9M
- BEAT 62.7M
- IPO Year
- ALRN 2017
- BEAT 2021
- Fundamental
- Price
- ALRN $3.42
- BEAT $2.27
- Analyst Decision
- ALRN Strong Buy
- BEAT Buy
- Analyst Count
- ALRN 1
- BEAT 1
- Target Price
- ALRN $19.00
- BEAT $8.00
- AVG Volume (30 Days)
- ALRN 93.8K
- BEAT 99.5K
- Earning Date
- ALRN 11-26-2024
- BEAT 11-07-2024
- Dividend Yield
- ALRN N/A
- BEAT N/A
- EPS Growth
- ALRN N/A
- BEAT N/A
- EPS
- ALRN N/A
- BEAT N/A
- Revenue
- ALRN N/A
- BEAT N/A
- Revenue This Year
- ALRN N/A
- BEAT N/A
- Revenue Next Year
- ALRN N/A
- BEAT N/A
- P/E Ratio
- ALRN N/A
- BEAT N/A
- Revenue Growth
- ALRN N/A
- BEAT N/A
- 52 Week Low
- ALRN $1.57
- BEAT $1.06
- 52 Week High
- ALRN $7.42
- BEAT $3.39
- Technical
- Relative Strength Index (RSI)
- ALRN 47.41
- BEAT 46.37
- Support Level
- ALRN $3.37
- BEAT $2.33
- Resistance Level
- ALRN $3.92
- BEAT $2.61
- Average True Range (ATR)
- ALRN 0.35
- BEAT 0.19
- MACD
- ALRN -0.06
- BEAT -0.02
- Stochastic Oscillator
- ALRN 21.36
- BEAT 9.80
About ALRN Aileron Therapeutics Inc.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.